Gefitinib
- Generic Name
- Gefitinib
- Brand Names
- Iressa, Gefitinib Mylan
- Drug Type
- Small Molecule
- Chemical Formula
- C22H24ClFN4O3
- CAS Number
- 184475-35-2
- Unique Ingredient Identifier
- S65743JHBS
- Background
Gefitinib (originally coded ZD1839) is a drug used in the treatment of certain types of cancer. Acting in a similar manner to erlotinib (marketed as Tarceva), gefitinib selectively targets the mutant proteins in malignant cells. It is marketed by AstraZeneca under the trade name Iressa.
- Indication
For the continued treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of either platinum-based or docetaxel chemotherapies.
- Associated Conditions
- Metastatic Non-Small Cell Lung Cancer
- Associated Therapies
- -
A Precision Medicine Approach (SMMART-ACT) for the Treatment of Patients With Advanced Sarcoma, Prostate, Breast, Ovarian or Pancreatic Cancer
- Conditions
- Advanced Breast CarcinomaAdvanced Malignant Solid NeoplasmAdvanced Ovarian CarcinomaAdvanced Pancreatic CarcinomaAdvanced Prostate CarcinomaAdvanced SarcomaAnatomic Stage III Breast Cancer AJCC v8Anatomic Stage IV Breast Cancer AJCC v8Stage III Ovarian Cancer AJCC v8Stage III Pancreatic Cancer AJCC v8
- Interventions
- Drug: AbemaciclibProcedure: BiopsyProcedure: Biospecimen CollectionDrug: FulvestrantProcedure: Bone ScanDrug: CarboplatinDrug: OlaparibProcedure: EchocardiographyDrug: GemcitabineDrug: PemetrexedDrug: ExemestaneDrug: LetrozoleDrug: GefitinibProcedure: Multigated Acquisition ScanOther: Survey AdministrationDrug: TamoxifenDrug: TemozolomideDrug: PaclitaxelDrug: OsimertinibDrug: Pegylated Liposomal Doxorubicin Hydrochloride
- First Posted Date
- 2024-10-08
- Last Posted Date
- 2024-12-18
- Lead Sponsor
- OHSU Knight Cancer Institute
- Target Recruit Count
- 30
- Registration Number
- NCT06630325
- Locations
- 🇺🇸
OHSU Knight Cancer Institute, Portland, Oregon, United States
A Study to Learn About the Effectiveness of Cancer Medicines in Patients With Metastatic Non-small Cell Lung Cancer in Norway.
- Conditions
- Interventions
- First Posted Date
- 2023-04-28
- Last Posted Date
- 2023-10-10
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 20605
- Registration Number
- NCT05834348
- Locations
- 🇳🇴
Pfizer Norway, Oslo, Norway
Bevacizumab Plus EGFR-TKIs in Chinese Patients With EGFR-mutant NSCLC: a Real-world Study
- First Posted Date
- 2020-10-05
- Last Posted Date
- 2020-10-20
- Lead Sponsor
- Guangdong Association of Clinical Trials
- Target Recruit Count
- 272
- Registration Number
- NCT04575415
- Locations
- 🇨🇳
Guangdong Provincial People's Hospital, Guangzhou, Guangdong, China
Bevacizumab Combined With Gefitinib in the Treatment of Advanced NSCLC
- First Posted Date
- 2020-06-11
- Last Posted Date
- 2020-06-12
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 120
- Registration Number
- NCT04425187
- Locations
- 🇨🇳
Cancer hospital Fudan University, Shanghai, Shanghai, China
Gefitinib With Anlotinib in Advanced Non-squamous NSCLC Patients With Uncleared Plasma ctDNA EGFRm After First-line Treatment With Gefitinib
- Conditions
- Interventions
- First Posted Date
- 2020-04-24
- Last Posted Date
- 2020-04-24
- Target Recruit Count
- 240
- Registration Number
- NCT04358562
- Locations
- 🇨🇳
The Second Afiliated Hospital of Nanchang University, Nanchang, Jiangxi, China
A Study of SH-1028 Tablets Versus Gefitinib in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2020-01-27
- Last Posted Date
- 2020-01-27
- Lead Sponsor
- Nanjing Sanhome Pharmaceutical, Co., Ltd.
- Target Recruit Count
- 240
- Registration Number
- NCT04239833
ASK120067 Versus Gefitinib as First-line Treatment for EGFRm Locally Advanced or Metastatic NSCLC
- Conditions
- Interventions
- First Posted Date
- 2019-10-29
- Last Posted Date
- 2024-06-14
- Lead Sponsor
- Jiangsu Aosaikang Pharmaceutical Co., Ltd.
- Target Recruit Count
- 337
- Registration Number
- NCT04143607
- Locations
- 🇨🇳
Jiangsu Cancer Hospital, Nanjing, Jiangsu, China
🇨🇳Chinese Academy of Medical Sciences, Beijing, Beijing, China
🇨🇳Beijing Chest Hospital,Capital Medical University, Beijing, Beijing, China
Gefitinib in Combination With Anlotinib or Placebo in Previously Untreated EGFR-mutant NSCLC
- Conditions
- Interventions
- First Posted Date
- 2019-07-23
- Last Posted Date
- 2019-11-08
- Lead Sponsor
- Sun Yat-sen University
- Target Recruit Count
- 310
- Registration Number
- NCT04028778
- Locations
- 🇨🇳
Cancer Center of Sun Yat-Sen University (CCSU), Guangzhou, Guangdong, China
Phase 2 Platform Study in Patients With Advanced Non-Small Lung Cancer Who Progressed on First-Line Osimertinib Therapy (ORCHARD)
- Conditions
- Interventions
- First Posted Date
- 2019-05-10
- Last Posted Date
- 2024-07-17
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 248
- Registration Number
- NCT03944772
- Locations
- 🇸🇪
Research Site, Stockholm, Sweden
A Study of BPI-7711 Capsule in Non-small Cell Lung Cancer Patients
- Conditions
- Interventions
- First Posted Date
- 2019-03-07
- Last Posted Date
- 2024-08-07
- Lead Sponsor
- Beta Pharma Shanghai
- Target Recruit Count
- 369
- Registration Number
- NCT03866499
- Locations
- 🇨🇳
Cancer Hospital Chinese Academy of Medical Sciences, Beijing, Beijing, China
🇨🇳The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China
🇨🇳Linyi Cancer Hospital, Linyi, Shandong, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.